SANGAMO THERAPEUTICS, INC
No enriched coverage for $SGMOQ in the last 7 days.
No SEC Form 4 filings for $SGMOQ in the last 30 days.
See all $SGMOQ insider activity →Sangamo Therapeutics (SGMOQ) initiated an auction for its ST-503 program, targeting chronic pain treatment, with completion expected in Q4 2026. The company previously sold assets to PTC and Lilly, generating $163.55 million. Sangamo is operating under Chapter 11 bankruptcy protection.
SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.03 Bankruptcy or Receivership. The information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Compan
SANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2
Recent SGMOQ coverage spans mergers & acquisitions and corporate actions.
Sangamo Therapeutics (SGMOQ) initiated an auction for its ST-503 program, targeting chronic pain treatment, with completion expected in Q4 2026. The company previously sold assets to PTC and Lilly, generating $163.55 million. Sangamo is operating under Chapter 11 bankruptcy protection.
The asset sale removes Sangamo's primary Fabry disease program and provides cash, but the company remains in Chapter 11 with suspended Nasdaq listing, likely pressuring the OTC share price lower.
The filing confirms asset disposition in Chapter 11, indicating ongoing restructuring and potential dilution for existing shareholders.
The cash infusion aids Sangamo’s Chapter 11 restructuring and may lift the distressed stock.
The asset sale removes Sangamo's Fabry disease program and associated liabilities, providing immediate cash but reducing future upside.
AlphAI scores every news story that mentions SGMOQ with an AI model for sentiment and relevance, and aggregates insider trades from SANGAMO THERAPEUTICS, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Sangamo Therapeutics (SGMOQ) initiated an auction for its ST-503 program, targeting chronic pain treatment, with completion expected in Q4 2026. The company previously sold assets to PTC and Lilly, generating $163.55 million. Sangamo is operating under Chapter 11 bankruptcy protection.
2 min readSANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Item 1.03 Bankruptcy or Receivership. The information set forth under Item 2.01 below is incorporated into this Item 1.03 by reference. Item 2.01 Completion of Acquisition or Disposition of Assets. As previously disclosed, on June 23, 2026, Sangamo Therapeutics, Inc. (the “Compan
2 min readSANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 UST Form 11-MOR (12/01/2021) 1 UNITED STATES BANKRUPTCY COURT DISTRICT OF DELAWARE In Re. SANGAMO THERAPEUTICS, INC. Debtor(s) § § § § Case No. 26-10989 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 07/31/2026 Petition Date: 06/23/2
1 min readSangamo Therapeutics (SGMOQ) sold its Fabry disease gene therapy program to PTC Therapeutics for $111M upfront, with up to $100M in milestones. The deal is part of Sangamo's Chapter 11 restructuring, with a bankruptcy court hearing scheduled for September 10, 2026. The transaction is subject to court approval and regulatory milestones.
2 min readSANGAMO THERAPEUTICS, INC (SGMOQ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K under the heading “PTC Asset Purchase Agreement” is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. As previously announc
2 min read
